Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Organon & (OGN)

Organon appoints Ramona A. Sequeira to board, effective July 1, 2025

Neutral Impact 2 of 5 leadership Written later

Organon & Co. said its board will expand by one seat to 12 directors, and Ramona A. Sequeira will fill the new seat effective July 1, 2025. Sequeira is a former Eli Lilly and Takeda executive, and she will join the board's Talent Committee, which may matter to shareholders as a change in board composition.

Key points

  • Board size increases by one, to 12 directors, effective July 1, 2025.
  • Ramona A. Sequeira previously spent 20 years at Eli Lilly and 10 years at Takeda, where she is President of the Global Portfolio Division.
  • Sequeira will serve on the Talent Committee and receive pro-rated cash compensation for 2025 under the director compensation program.

The filing

CompanyOrganon & (OGN)
Form8-K, current report
Filed with the SECApr 15, 2025, 5:05 PM ET
Accession number0001104659-25-035173

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 15, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.